Textural parameters of tumor heterogeneity in18F-FDG PET/CT for therapy response assessment and prognosis in patients with locally advanced rectal cancer

Journal of Nuclear Medicine

Volumn 55, Issue 6, 2014, Pages 891-897

  Bundschuh, Ralph A ^a,b,c   Dinges, Julia ^a   Neumann, Larissa ^a   Seyfried, Martin ^a   Zsótér, Norbert ^d   Papp, Laszló ^d   Rosenberg, Robert ^e   Becker, Karen ^a   Astner, Sabrina T ^a   Henninger, Martin ^a   Herrmann, Ken ^b   Ziegler, Sibylle I ^a   Schwaiger, Markus ^a   Essler, Markus ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d Mediso Medical Imaging Systems Ltd   (Hungary)

^e Chirurgische Klinik Stadtspital Waid   (Switzerland)

Author keywords

Coefficient of variation; Prognostic parameter; Rectal cancer; Therapy monitoring; Tumor heterogeneity

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER CELL POPULATION HETEROGENEITY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COEFFICIENT OF VARIATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; MAXIMUM STANDARDIZED UPTAKE VALUE; MEAN STANDARDIZED UPTAKE VALUE; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CANCER; SENSITIVITY AND SPECIFICITY; SKEWNESS; SURVIVAL TIME; TOTAL LESION GLYCOLYSIS; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; FEMALE; KAPLAN MEIER METHOD; MALE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RECTAL NEOPLASMS; SCINTISCANNING; TREATMENT OUTCOME;

CHEMORADIOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RECTAL NEOPLASMS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84903122418     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.127340     Document Type: Article

References (24)

1. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
2. Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging. 2012;3:573-589.
3. Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853-860.
4. Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2012;22:796-802.
5. Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology. 2011;261:165-171.
6. O'Connor JP, Rose CJ, Jackson A, et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer. 2011;105:139-145.
7. Lopes R, Ayache A, Makni N, et al. Prostate cancer characterization on MR images using fractal features. Med Phys. 2011;38:83-95.
8. 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133-140.
9. Martinez MJ, Bercier Y, Schwaiger M, Ziegler SI. PET/CT Biograph Sensation 16: performance improvement using faster electronics. Nuklearmedizin. 2006;3:126-133. (Pubitemid 44047833)
10. Jakoby BW, Bercier Y, Conti M, Casey ME, Bendriem B, Townsend DW. Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol. 2011;56:2375-2389.
11. 18F-FDG uptake as a predictor of patient outcome. J Nucl Med. 2008;49:1973-1979.
12. 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369-378.
13. 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19-26.
14. Yu H, Caldwell C, Mah K, Mozeg D. Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging. 2009;28:374-383.
15. Rosenberg R, Herrmann K, Gertler R, et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191-200.
16. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530. (Pubitemid 37151509)
17. Herrmann K, Bundschuh RA, Rosenberg R, et al. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol. 2011;13:1011-1019.
18. Isoda T, Abe K, Baba S, et al. Prediction of tumor response to chemoradiation with coefficient of variation of FDG uptake in metastatic lymph nodes in the patients with pharyngeal cancer [abstract]. J Nucl Med. 2012;53(suppl):283P.
19. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36. (Pubitemid 12142173)
21. 18F-FDG PET. J Nucl Med. 2012;53:693-700.
22. Herrmann K, Krause BJ, Bundschuh RA, Dechow T, Schwaiger M. Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med. 2009;39:210-232.
23. Black QC, Grills IS, Kestin LL, et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys. 2004;60:1272-1282. (Pubitemid 39440814)
24. 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182-193.